A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-cancer Pain
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2017
At a glance
- Drugs NKTR 181 (Primary)
- Indications Back pain; Pain
- Focus Adverse reactions; Registrational
- Acronyms SUMMIT-LTS
- Sponsors Nektar Therapeutics
- 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2016 Planned number of patients changed from 600 to 640.
- 03 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2018.